[{"id":"9678854b-d3b2-42be-bf3d-1cdfa6e7652f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05557877","created_at":"2024-04-24T19:42:10.923Z","updated_at":"2025-02-25T17:38:07.530Z","phase":"Phase 2","brief_title":"Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer","source_id_and_acronym":"NCT05557877","lead_sponsor":"Mayo Clinic","biomarkers":" ER • CRP","pipe":"","alterations":" ","tags":["ER • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/09/2023","start_date":" 03/09/2023","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2027","study_completion_date":" 01/30/2027","last_update_posted":"2025-01-28"},{"id":"ac4c8720-90f3-4cfe-bd1a-08988315c11c","acronym":"REPROGRAM-01","url":"https://clinicaltrials.gov/study/NCT04534218","created_at":"2021-01-18T21:42:20.525Z","updated_at":"2025-02-25T17:24:47.487Z","phase":"Phase 2","brief_title":"Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04534218 - REPROGRAM-01","lead_sponsor":"Centre Hospitalier Universitaire de Besancon","biomarkers":" KRAS","pipe":" | ","alterations":" RAS wild-type • NRAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • cyclophosphamide • Stivarga (regorafenib) • aspirin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 10/16/2020","start_date":" 10/16/2020","primary_txt":" Primary completion: 12/13/2023","primary_completion_date":" 12/13/2023","study_txt":" Completion: 12/13/2023","study_completion_date":" 12/13/2023","last_update_posted":"2024-12-20"},{"id":"23dbdc8e-972e-4762-87c9-f40d67d274d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05080946","created_at":"2021-10-18T12:53:00.791Z","updated_at":"2024-07-02T16:34:26.049Z","phase":"Phase 1","brief_title":"Using Aspirin to Improve Immunological Features of Ovarian Tumors","source_id_and_acronym":"NCT05080946","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD163 • FOXP3","pipe":"","alterations":" ","tags":["CD163 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/02/2021","start_date":" 11/02/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-14"},{"id":"7bc6ad53-4099-4558-b378-de14c0987660","acronym":"AIRPORT-MPN","url":"https://clinicaltrials.gov/study/NCT04243122","created_at":"2021-01-18T20:37:43.640Z","updated_at":"2024-07-02T16:35:00.279Z","phase":"Phase 2","brief_title":"Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients","source_id_and_acronym":"NCT04243122 - AIRPORT-MPN","lead_sponsor":"Ottawa Hospital Research Institute","biomarkers":" JAK2","pipe":"","alterations":" ","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 02/17/2021","start_date":" 02/17/2021","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 05/03/2024","study_completion_date":" 05/03/2024","last_update_posted":"2024-05-29"},{"id":"4ffad9ac-b9ad-4a72-be3d-2530bfde2f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03480776","created_at":"2021-01-18T17:09:00.672Z","updated_at":"2024-07-02T16:35:12.838Z","phase":"Phase 2","brief_title":"ASA in Prevention of Ovarian Cancer (STICs and STONEs)","source_id_and_acronym":"NCT03480776","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 07/24/2018","start_date":" 07/24/2018","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 09/15/2025","study_completion_date":" 09/15/2025","last_update_posted":"2024-03-26"},{"id":"bc0ab9aa-dfd0-4ac8-8031-f30fc9f954e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05411718","created_at":"2022-06-09T13:55:29.609Z","updated_at":"2024-07-02T16:35:15.093Z","phase":"Phase 2","brief_title":"A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome","source_id_and_acronym":"NCT05411718","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/21/2023","start_date":" 03/21/2023","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-03-13"},{"id":"b4b2fabf-333a-456a-a058-b135346152b4","acronym":"ALASCCA","url":"https://clinicaltrials.gov/study/NCT02647099","created_at":"2021-01-18T12:52:53.182Z","updated_at":"2024-07-02T16:35:15.603Z","phase":"Phase 3","brief_title":"Adjuvant Low Dose Aspirin in Colorectal Cancer","source_id_and_acronym":"NCT02647099 - ALASCCA","lead_sponsor":"Anna Martling","biomarkers":" PIK3CA • PTEN • PIK3R1","pipe":"","alterations":" ","tags":["PIK3CA • PTEN • PIK3R1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 04/07/2016","start_date":" 04/07/2016","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-03-08"},{"id":"dd3d4d67-0859-4f46-b395-3bf18f2f7dc2","acronym":"RACIN","url":"https://clinicaltrials.gov/study/NCT03728179","created_at":"2021-01-18T18:16:01.559Z","updated_at":"2024-07-02T16:35:18.689Z","phase":"Phase 1","brief_title":"RACIN in Patients With Advanced TIL-negative Solid Tumors","source_id_and_acronym":"NCT03728179 - RACIN","lead_sponsor":"Centre Hospitalier Universitaire Vaudois","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • aspirin • celecoxib oral • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 01/16/2019","start_date":" 01/16/2019","primary_txt":" Primary completion: 10/27/2023","primary_completion_date":" 10/27/2023","study_txt":" Completion: 10/27/2023","study_completion_date":" 10/27/2023","last_update_posted":"2024-02-20"},{"id":"2bdd752e-e61e-42b2-941d-7d28dae7f2cb","acronym":"SAKK 41/13","url":"https://clinicaltrials.gov/study/NCT02467582","created_at":"2021-01-18T11:52:41.622Z","updated_at":"2024-07-02T16:35:23.344Z","phase":"Phase 3","brief_title":"Adjuvant Aspirin Treatment for Colon Cancer Patients","source_id_and_acronym":"NCT02467582 - SAKK 41/13","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 185","initiation":"Initiation: 06/09/2016","start_date":" 06/09/2016","primary_txt":" Primary completion: 09/14/2023","primary_completion_date":" 09/14/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-17"},{"id":"4d8663fb-c0ac-4fa9-9514-5c1ff4a7ba20","acronym":"ResToP","url":"https://clinicaltrials.gov/study/NCT04160546","created_at":"2021-01-18T20:17:33.899Z","updated_at":"2024-07-02T16:35:25.034Z","phase":"Phase 2","brief_title":"Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)","source_id_and_acronym":"NCT04160546 - ResToP","lead_sponsor":"Fundacion CRIS de Investigación para Vencer el Cáncer","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib) • aspirin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 01/17/2020","start_date":" 01/17/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-28"},{"id":"e4220b6f-ddea-48c7-82cd-c17cdfe4a38e","acronym":"REPROGRAM-02","url":"https://clinicaltrials.gov/study/NCT05462613","created_at":"2022-07-18T14:01:46.785Z","updated_at":"2024-07-02T16:35:25.412Z","phase":"Phase 2/3","brief_title":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05462613 - REPROGRAM-02","lead_sponsor":"Centre Hospitalier Universitaire de Besancon","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • capecitabine • cyclophosphamide • Stivarga (regorafenib) • irinotecan • leucovorin calcium • aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 446","initiation":"Initiation: 05/09/2023","start_date":" 05/09/2023","primary_txt":" Primary completion: 11/01/2029","primary_completion_date":" 11/01/2029","study_txt":" Completion: 11/01/2030","study_completion_date":" 11/01/2030","last_update_posted":"2023-12-22"},{"id":"807674cf-1bc0-43eb-bae4-f7928e8936a0","acronym":"Pro00011685","url":"https://clinicaltrials.gov/study/NCT02834403","created_at":"2021-01-18T13:54:35.762Z","updated_at":"2024-07-02T16:35:26.085Z","phase":"Phase 1/2","brief_title":"L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT02834403 - Pro00011685","lead_sponsor":"The Methodist Hospital Research Institute","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation • ER negative • PGR negative","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Neulasta (pegfilgrastim) • tilarginine (L-NMMA) • aspirin"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 01/01/2021","study_completion_date":" 01/01/2021","last_update_posted":"2023-12-15"},{"id":"b01abc76-a9b1-4a0e-8d3d-7c94aad01cf8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02804815","created_at":"2021-01-18T13:45:12.829Z","updated_at":"2024-07-02T16:35:27.565Z","phase":"Phase 3","brief_title":"Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours","source_id_and_acronym":"NCT02804815","lead_sponsor":"University College, London","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • HER-2 negative • HR negative • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • HER-2 negative • HR negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 11000","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-11-30"},{"id":"97d535c2-613d-4bea-bd1b-97d4e14f968f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02965703","created_at":"2021-01-18T14:34:35.708Z","updated_at":"2024-07-02T16:35:31.010Z","phase":"Phase 2","brief_title":"Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma","source_id_and_acronym":"NCT02965703","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BAX","pipe":"","alterations":" ","tags":["BCL2 • BAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 01/16/2018","start_date":" 01/16/2018","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2023-10-31"},{"id":"ccb06581-c785-4000-99c5-afd562ceab63","acronym":"","url":"https://clinicaltrials.gov/study/NCT06018688","created_at":"2023-08-31T14:10:09.463Z","updated_at":"2024-07-02T16:35:36.234Z","phase":"Phase 2","brief_title":"Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.","source_id_and_acronym":"NCT06018688","lead_sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • aspirin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 09/15/2023","start_date":" 09/15/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-09-21"},{"id":"8123b2d2-deaa-462c-ba64-a6b226fc5dcf","acronym":"IMpALA","url":"https://clinicaltrials.gov/study/NCT04188119","created_at":"2021-01-18T20:24:53.381Z","updated_at":"2024-07-02T16:35:47.784Z","phase":"Phase 2","brief_title":"A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer","source_id_and_acronym":"NCT04188119 - IMpALA","lead_sponsor":"The Christie NHS Foundation Trust","biomarkers":" HER-2 • ER • PGR • PTGS2","pipe":" | ","alterations":" HER-2 negative • PTGS2 expression","tags":["HER-2 • ER • PGR • PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PTGS2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • aspirin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2023-05-17"},{"id":"4d95ba7d-235d-4c76-9c30-eae94461392a","acronym":"AAS-Lynch","url":"https://clinicaltrials.gov/study/NCT02813824","created_at":"2021-01-18T13:48:03.647Z","updated_at":"2024-07-02T16:36:08.238Z","phase":"Phase 3","brief_title":"Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome","source_id_and_acronym":"NCT02813824 - AAS-Lynch","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" MLH1 • MSH6 • MSH2 • PMS2","pipe":"","alterations":" ","tags":["MLH1 • MSH6 • MSH2 • PMS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 852","initiation":"Initiation: 11/14/2017","start_date":" 11/14/2017","primary_txt":" Primary completion: 06/15/2026","primary_completion_date":" 06/15/2026","study_txt":" Completion: 12/15/2027","study_completion_date":" 12/15/2027","last_update_posted":"2022-06-28"},{"id":"7ffa6ace-b0b0-443f-b9f3-6dc823650411","acronym":"Breast 51","url":"https://clinicaltrials.gov/study/NCT04038489","created_at":"2021-01-18T19:48:49.593Z","updated_at":"2024-07-02T16:36:20.438Z","phase":"Phase 2","brief_title":"COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer","source_id_and_acronym":"NCT04038489 - Breast 51","lead_sponsor":"University of Virginia","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • aspirin • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/18/2019","start_date":" 10/18/2019","primary_txt":" Primary completion: 04/30/2023","primary_completion_date":" 04/30/2023","study_txt":" Completion: 04/30/2023","study_completion_date":" 04/30/2023","last_update_posted":"2021-11-22"},{"id":"6f8ede38-e501-4f64-9cdf-e37b5d5c9b94","acronym":"","url":"https://clinicaltrials.gov/study/NCT02326779","created_at":"2021-01-18T11:02:21.157Z","updated_at":"2024-07-02T16:36:31.162Z","phase":"Phase 3","brief_title":"Low-dose Aspirin Therapy for Esophageal Cancer","source_id_and_acronym":"NCT02326779","lead_sponsor":"Zhejiang University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 10/01/2018","primary_completion_date":" 10/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2021-04-27"},{"id":"d38d80fd-2193-4e8f-b01f-48d83c635869","acronym":"","url":"https://clinicaltrials.gov/study/NCT04184921","created_at":"2021-01-18T20:24:03.292Z","updated_at":"2024-07-02T16:36:42.842Z","phase":"","brief_title":"Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients","source_id_and_acronym":"NCT04184921","lead_sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • aspirin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 08/01/2020","start_date":" 08/01/2020","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2020-07-23"},{"id":"73552f87-164d-42a3-b749-7eef35e0b7c2","acronym":"ASPIK French","url":"https://clinicaltrials.gov/study/NCT02945033","created_at":"2022-01-05T22:01:00.037Z","updated_at":"2024-07-02T16:36:54.260Z","phase":"Phase 3","brief_title":"Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk","source_id_and_acronym":"NCT02945033 - ASPIK French","lead_sponsor":"University Hospital, Rouen","biomarkers":" PI3K","pipe":"","alterations":" ","tags":["PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 264","initiation":"Initiation: 07/12/2018","start_date":" 07/12/2018","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2019-10-24"},{"id":"932b6758-a290-4d1d-8d85-a12ec556b765","acronym":"","url":"https://clinicaltrials.gov/study/NCT00983580","created_at":"2021-01-18T03:50:19.599Z","updated_at":"2024-07-02T16:36:55.983Z","phase":"Phase 2","brief_title":"Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer","source_id_and_acronym":"NCT00983580","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 08/20/2009","start_date":" 08/20/2009","primary_txt":" Primary completion: 10/07/2016","primary_completion_date":" 10/07/2016","study_txt":" Completion: 08/13/2019","study_completion_date":" 08/13/2019","last_update_posted":"2019-09-04"},{"id":"8498b86c-2eff-434b-a67f-e0f9f3688490","acronym":"IMpALA","url":"https://clinicaltrials.gov/study/NCT03794596","created_at":"2021-01-18T18:45:48.955Z","updated_at":"2024-07-02T16:36:57.894Z","phase":"Phase 2","brief_title":"A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer","source_id_and_acronym":"NCT03794596 - IMpALA","lead_sponsor":"The Christie NHS Foundation Trust","biomarkers":" HER-2 • ER • PGR • PTGS2","pipe":" | ","alterations":" HER-2 negative • PTGS2 expression","tags":["HER-2 • ER • PGR • PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PTGS2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • aspirin"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 02/28/2021","primary_completion_date":" 02/28/2021","study_txt":" Completion: 02/28/2021","study_completion_date":" 02/28/2021","last_update_posted":"2019-07-22"},{"id":"c2127c94-b5aa-4264-be7a-ee93fa6a03a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01259856","created_at":"2021-01-18T05:04:56.061Z","updated_at":"2024-07-02T16:37:00.069Z","phase":"Phase 3","brief_title":"Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)","source_id_and_acronym":"NCT01259856","lead_sponsor":"Ronald Hoffman","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a) • hydroxyurea • aspirin"],"overall_status":"Completed","enrollment":" Enrollment 168","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 06/30/2017","primary_completion_date":" 06/30/2017","study_txt":" Completion: 06/30/2017","study_completion_date":" 06/30/2017","last_update_posted":"2019-04-30"}]